The Latest in B Cell Lymphoma

KTE-X19 produces highest response rate in MCL subgroup

December 14, 2019

An off-the-shelf drug to rival CAR T cells: ‘very exciting’

December 13, 2019

B Cell Lymphoma

Orelabrutinib could be ‘preferred’ BTK inhibitor for MCL

December 12, 2019

Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL

December 10, 2019

Off-the-shelf cellular therapy shows promise in the lab

December 8, 2019

Newly identified genetic changes contribute to transformation of follicular lymphoma

December 7, 2019

SOX11 shows value as diagnostic marker in MCL

December 4, 2019

Acalabrutinib may outperform other targeted therapies in MCL

December 4, 2019

FDA approves acalabrutinib for CLL, SLL treatment

November 21, 2019

Frontline ibrutinib saves money over chemoimmunotherapy

November 20, 2019

Rituximab maintenance has a durable benefit in follicular lymphoma

November 19, 2019

CAR T-cell ‘cocktail’ may overcome antigen escape relapse

November 18, 2019

B Cell Lymphoma

Adding polatuzumab extends survival in relapsed/refractory DLBCL

November 16, 2019

FDA approves Brukinsa for relapsed, refractory MCL

November 15, 2019

Gene signature may help guide initial CLL treatment choice

November 14, 2019